Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy of GSK Biologicals' candidate tuberculosis (TB) vaccine GSK 692342 against TB disease, in healthy adults living in a TB endemic region

Trial Profile

Efficacy of GSK Biologicals' candidate tuberculosis (TB) vaccine GSK 692342 against TB disease, in healthy adults living in a TB endemic region

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Feb 2019

At a glance

  • Drugs GSK 692342 (Primary)
  • Indications Tuberculosis
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 04 Feb 2019 Status changed from active, no longer recruiting to completed.
    • 07 Oct 2018 Results presented at the IDWeek 2018
    • 25 Sep 2018 Primary endpoint (Incident cases of definite pulmonary TB disease not associated with HIV-infection meeting the first case definition.) has been met, according to the results published in the New England Journal of Medicine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top